How much is ImmunoGenesis worth in 2025?

ImmunoGenesis has a current valuation of N/A based on their Unknown round and secondary market data.

How much funding has ImmunoGenesis raised?

ImmunoGenesis has raised N/A in total funding across 1 funding rounds.

ImmunoGenesis

Last updated: N/A

Current Valuation

N/A

Total Funding Raised

N/A

Across 1 round

Last Round

Unknown

Amount undisclosed

Last Funding

Unknown

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
N/A	Unknown	Undisclosed	N/A	-

Valuation Analysis

Current Valuation Metrics

ImmunoGenesis is currently valued at N/A.

Investment Perspective

ImmunoGenesis's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.

Track ImmunoGenesis Valuation Updates

Get notified when ImmunoGenesis raises new funding or valuation changes

Explore More Data

Detailed analysis for ImmunoGenesis

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

What is ImmunoGenesis Worth in 2025?

As of 2025, ImmunoGenesis is valued at N/A. This valuation positions ImmunoGenesis as one of the leading private companies in the sector.

ImmunoGenesis Valuation History

ImmunoGenesis has completed 1 funding round.

How ImmunoGenesis Valuation is Determined

Private company valuations like ImmunoGenesis's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:

Revenue growth and financial performance
Market opportunity and total addressable market (TAM)
Competitive positioning and market share
Management team strength and execution capability
Technology and intellectual property
Industry trends and investor sentiment

ImmunoGenesis Valuation FAQs

Is ImmunoGenesis profitable?

ImmunoGenesis has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.

How does ImmunoGenesis's valuation compare to competitors?

ImmunoGenesis is valued at N/A, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.

When will ImmunoGenesis IPO?

ImmunoGenesis has not announced plans for an initial public offering. Until an IPO, investors can access ImmunoGenesis shares through secondary market platforms.